Genentech Reports Data from P-III (BALATON and COMINO) Trials of Vabysmo (faricimab-svoa) for Macular Edema due to Retinal Vein Occlusion
Shots:
- Genentech reported updated 72wks. data from the P-III (BALATON; n=553) & (COMINO; n=729) trials for the safety and efficacy of Vabysmo vs aflibercept to treat branch retinal vein occlusion and central retinal vein occlusion respectively
- The results from the P-III (BALATON) trial showed a vision gain of 18.1 letters and a reduction of 310.9µm in retinal swelling with Vabysmo as a 1L treatment while switching from aflibercept to Vabysmo revealed a vision gain of 18.8 letters and 307µm reduction in CST
- The data from the P-III (COMINO) trial showed a vision gain of 16.9 letters and a reduction of 465.9µm in retinal swelling with Vabysmo as a 1L treatment while switching from aflibercept to Vabysmo revealed a vision gain of 17.1 letters and 460.6µm reduction in CST
Ref: Genentech | Image: Genentech
Related News:- Genentech’s Vabysmo (faricimab-svoa) Receives the US FDA’s Approval for the Treatment of Retinal Vein Occlusion
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
